Skip to main content

Table 4 Relative efficacy versus abatacept + MTX at 24/26 and 48/54 weeks

From: Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Treatment effect relative to Abatacept + MTX

Difference in mean HAQ CFB

at 24/26 weeks

(95% CrL)*

Difference in mean HAQ CFB

at 48/54 weeks

(95% CrL)**

OR for ACR-50

at 24/26 weeks

(95% CrL)*

OR for ACR-50

at 48/54 weeks

(95% CrL)**

OR for DAS28 < 2.6

at 24/26 weeks

(95% CrL)*

OR for DAS28 < 2.6

at 48/54 weeks

(95% CrL)*

Placebo + MTX

-0.30

(-0.41; -0.18)

-0.29

(-0.38; -0.21)

3.37

(1.49; 8.06)

3.84

(2.84; 5.26)

4.77

(1.60; 15.78)

8.82

(1.50; 57.83)

Adalimumab + MTX

0.03

(-0.16; 0.24)

0.05

(-0.09; 0.18)

0.40

(0.09; 1.50)

0.56

(0.29; 1.03)

  

Certolizumab Pegol + MTX

0.08

(-0.09; 0.28)

0.13

(-0.00; 0.26)

0.35

(0.08; 1.33)

0.51

(0.26; 0.96)

0.26

(0.01; 3.90)

 

Etanercept + MTX

-0.02

(-0.24; 0.21)

0.05

(-0.22; 0.32)

1.05

(0.17; 3.24)

0.72

(0.43; 1.19)

1.69

(0.21; 15.80)

2.94

(0.14; 67.12)

Golimumab + MTX

0.04

(-0.21; 0.30)

 

0.87

(0.16; 5.15)

 

1.18

(0.13; 11.66)

 

Infliximab + MTX

-0.11

(-0.29; 0.08)

-0.11

(-0.22; 0.01)

1.31

(0.27; 7.61)

1.40

(0.93; 2.10)

0.88

(0.09; 7.76)

1.68

(0.14; 21.23)

Rituximab + MTX

-0.09

(-0.31; 0.14)

0.01

(-0.34; 0.35)

0.85

(0.20; 3.47)

0.31

(0.04; 1.37)

  

Tocilizumab + MTX

-0.09

(-0.35; 0.18)

 

0.51

(0.10; 2.88)

 

0.05

(0.00; 0.79)

 
  1. Note: for HAQ CFB, negative values indicate a trend towards a clinical benefit for abatacept. For ACR-50 and DAS28 < 2.6, an OR > 1 indicates a trend towards a clinical benefit for abatacept.
  2. * Results based on a random effects model. ** Results based on a fixed effects model.
  3. OR, odds ratio; 95% CrL, 95% credible limits